A review of lipidation in the development of advanced protein and peptide therapeutics.
Published
Journal Article (Review)
The use of biologics (peptide and protein based drugs) has increased significantly over the past few decades. However, their development has been limited by their short half-life, immunogenicity and low membrane permeability, restricting most therapies to extracellular targets and administration by injection. Lipidation is a clinically-proven post-translational modification that has shown great promise to address these issues: improving half-life, reducing immunogenicity and enabling intracellular uptake and delivery across epithelia. Despite its great potential, lipidation remains an underutilized strategy in the clinical translation of lead biologics. We review how lipidation can overcome common challenges in biologics development as well as highlight gaps in our understanding of the effect of lipidation on therapeutic efficacy, where increased research and development efforts may lead to next-generation drugs.
Full Text
Duke Authors
Cited Authors
- Menacho-Melgar, R; Decker, JS; Hennigan, JN; Lynch, MD
Published Date
- February 2019
Published In
Volume / Issue
- 295 /
Start / End Page
- 1 - 12
PubMed ID
- 30579981
Pubmed Central ID
- 30579981
Electronic International Standard Serial Number (EISSN)
- 1873-4995
International Standard Serial Number (ISSN)
- 0168-3659
Digital Object Identifier (DOI)
- 10.1016/j.jconrel.2018.12.032
Language
- eng